Alimera Sciences
ALIM
ALIM was delisted on the 13th of September, 2024.
43 hedge funds and large institutions have $35.9M invested in Alimera Sciences in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
41% more capital inflows, than outflows
Capital inflows: $1.14M | Capital outflows: $805K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
16% more funds holding
Funds holding: 37 → 43 (+6)
0.46% more ownership
Funds ownership: 51.84% → 52.3% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B. Riley Financial
Los Angeles,
California
|
+$463K |
| 2 |
Royce & Associates
New York
|
+$202K |
| 3 |
Renaissance Technologies
New York
|
+$161K |
| 4 |
DMK
David M. Knott
|
+$58.8K |
| 5 |
Thompson Davis & Co
Richmond,
Virginia
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acuta Capital Partners
Redwood City,
California
|
-$717K |
| 2 |
Spark Investment Management
New York
|
-$41K |
| 3 |
Boothbay Fund Management
New York
|
-$19K |
| 4 |
Goldman Sachs
New York
|
-$8.84K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.28K |
ALIM Hedge Fund Activity: Q3 2018 in Review
43 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Alimera Sciences (ALIM) for Q3 2018, worth a combined $35.9M — up 1.1% from $35.5M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ALIM positions and 2 closed out — a net gain of 6 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was B. Riley Financial, opening a new position worth an estimated $463K. The largest seller was Acuta Capital Partners, cutting an estimated $717K.
- 43 institutional investors held Alimera Sciences (ALIM) as of Q3 2018, up from 37 in Q2 2018.
- Funds reported $35.9M of Alimera Sciences stock for Q3 2018, up 1.1% quarter-over-quarter.
- 8 funds opened new Alimera Sciences positions in Q3 2018 and 2 closed out, a net change of +6 holders.
- The largest Alimera Sciences buyer in Q3 2018 was B. Riley Financial, an estimated $463K added.
- The largest Alimera Sciences seller in Q3 2018 was Acuta Capital Partners, an estimated $717K sold.
Based on aggregated 13F filings for Q3 2018.